<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476189</url>
  </required_header>
  <id_info>
    <org_study_id>A2750607</org_study_id>
    <nct_id>NCT01476189</nct_id>
  </id_info>
  <brief_title>A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations</brief_title>
  <official_title>A Repeat Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A repeat dose pharmacokinetic study investigating two paracetamol formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence as measured by Area Under the Curve (AUC)</measure>
    <time_frame>last 24 hours of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time duration at or above minimal therapeutic plasma paracetamol concentration</measure>
    <time_frame>last 24 hours of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetic parameters (Cmax, AUC, Tmax and Kel)</measure>
    <time_frame>last 24 hours of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to 72 hours post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Experimental paracetamol formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>test formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marketed paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose marketed paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>higher dose marketed paracetamol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental paracetamol formulation</intervention_name>
    <description>experimental</description>
    <arm_group_label>Experimental paracetamol formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marketed paracetamol</intervention_name>
    <description>Marketed paracetamol</description>
    <arm_group_label>Marketed paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher dose marketed paracetamol</intervention_name>
    <description>Higher dose marketed paracetamol</description>
    <arm_group_label>Higher dose marketed paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health with (in the opinion of the investigator) no clinically
             significant and relevant abnormalities of medical history or physical examination.

        Exclusion Criteria:

          -  Subject does not agree to refrain from alcohol consumption for the 10-day period prior
             to visit 2 and throughout the study.

          -  Participation in another clinical study or receipt of an investigational drug within
             30 days of the screening visit.

          -  Current (within 14 days of screening) or regular use of any prescription,
             over-the-counter drugs including paracetamol/acetaminophen, herbal medicine or drug
             known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing
             (e.g. barbiturates, theophylline, cimetidine, or erythromycin), excluding prescription
             birth control, if applicable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services NEBRASKA</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>paracetamol</keyword>
  <keyword>Healthy volunteer</keyword>
  <keyword>steady state</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

